Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.5.1.3 (
dihydrofolate reductase
)
5,819
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The promoter of the human c-K-ras gene has been characterized by deletion mutagenesis in concert with stable and transient expression gene transfer experiments. The transcription initiation sites were determined by S1 mapping and
RNase A
protection experiments. The c-K-ras promoter region is rich in G + C, lacks TATA and CCAAT boxes and contains sequence similarities with other house-keeping genes such as the
dihydrofolate reductase
(
DHFR
) and the epidermal growth factor (EGF) receptor genes. The promoter of the c-K-ras gene consists of multiple elements and initiation of transcription occurs at multiple sites. A 54 bp DNA fragment immediately upstream from the 5' end untranslated exon controls the position of many of the transcription initiation sites and direct sufficient transcription for transformation of NIH3T3 cells. However, these sequences can be replaced by other upstream sequences which are required for optimal gene expression. In addition, sequences overlapping with the 5' end untranslated exon and therefore downstream from the major transcription initiation sites are important (although not sufficient) for transcription because their deletion greatly impairs the promoter activity of the upstream elements.
...
PMID:Characterization of the human c-K-ras gene promoter. 306 87
PA700, the 19 S regulatory complex of the 26 S proteasome, plays a central role in the recognition and efficient degradation of misfolded proteins. PA700 promotes degradation by recruiting proteasomal substrates utilizing polyubiquitin chains and chaperone-like binding activities and by opening the access to the core of the 20 S proteasome to promote degradation. Here we provide evidence that PA700 in addition to binding misfolded protein substrates also acts to remodel their conformation prior to proteolysis. Scrambled
RNase A
(scRNase A), a misfolded protein, only slowly refolds spontaneously into an active form because of the rate-limiting unfolding of misfolded disulfide isomers. Notably, PA700 accelerates the rate of reactivation of scRNase A, consistent with its ability to increase the exposure of these disulfide bonds to the solvent. In this regard, PA700 also exposes otherwise buried sites to digestion by exogenous chymotrypsin in a polyubiquitinated enzymatically active substrate, pentaubiquitinated
dihydrofolate reductase
, Ub(5)
DHFR
. The
dihydrofolate reductase
ligand methotrexate counters the ability of PA700 to promote digestion by chymotrypsin. Together, these results indicate that in addition to increasing substrate affinity and opening the access channel to the catalytic sites, PA700 activates proteasomal degradation by remodeling the conformation of protein substrates.
...
PMID:Conformational remodeling of proteasomal substrates by PA700, the 19 S regulatory complex of the 26 S proteasome. 1201 Oct 44